Home
Live Updates
Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce European Commission Authorization of PRX-102 (pegunigalsidase alfa) for the Treatment of Fabry Disease : comparemela.com
Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce European Commission Authorization of PRX-102 (pegunigalsidase alfa) for the Treatment of Fabry Disease
/PRNewswire/ -- Chiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people affected...
Related Keywords
United States ,
Boston ,
Massachusetts ,
Italy ,
France ,
China ,
Israel ,
Sweden ,
United Kingdom ,
Carmiel ,
Ha Afon ,
Brazil ,
Canada ,
American ,
Chiesi Farmaceutici ,
Chuck Padala ,
Diego Ardig ,
Dror Bashan ,
Alessio Pappagallo ,
Adam Daley ,
Chiara Travagin ,
Giacomo Chiesi ,
Protalix Biotherapeutics Inc ,
Chiesi Group ,
European Medicines Agency ,
Pfizer Inc ,
Drug Administration ,
Exchange Commission ,
European Commission ,
Berry Company Public Relations ,
Chiesi Group Media Contact ,
European Union ,
B Corp ,
Global Rare Diseases ,
Chiesi Global Rare ,
Chief Executive ,
Benefit Corporation ,
Private Securities Litigation Reform Act ,
Biologics License Application ,
Chiesi Global Rare Diseases Protalix Biotherapeutics ,
Nc ,
comparemela.com © 2020. All Rights Reserved.